‘A Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Service’

OBJECTIVE: Sodium-glucose co-transporter-2 inhibitors (SGLT2-I’s) are novel oral hypoglycaemic agents, with proven decreased MACE and re-hospitalisation risk in type 2 diabetic patients with concomitant heart failure. This study aimed to assess the current practice in the use of SGLT2-I’s in general...

Descripción completa

Detalles Bibliográficos
Autores principales: Perera, Padeepa, O’Donnabhain, Ronan, Fazio, Timothy, Johnson, Douglas, Lange, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623351/
https://www.ncbi.nlm.nih.gov/pubmed/36329805
http://dx.doi.org/10.1177/11795468221133607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623351/
https://www.ncbi.nlm.nih.gov/pubmed/36329805
http://dx.doi.org/10.1177/11795468221133607

Ejemplares similares